These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 16699494)

  • 1. Impact of genetic diagnostics on drug development strategy.
    Million RP
    Nat Rev Drug Discov; 2006 Jun; 5(6):459-62. PubMed ID: 16699494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Market watch: emerging companion diagnostics for cancer drugs.
    August J
    Nat Rev Drug Discov; 2010 May; 9(5):351. PubMed ID: 20431558
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalised medicine for cancer: from drug development into clinical practice.
    Jain KK
    Expert Opin Pharmacother; 2005 Aug; 6(9):1463-76. PubMed ID: 16086635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic pharmacogenomics in cancer.
    Ikediobi ON
    Pharmacogenomics J; 2008 Oct; 8(5):305-14. PubMed ID: 18679398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes.
    Amrein L; Soulières D; Johnston JB; Aloyz R
    Leuk Res; 2011 Jan; 35(1):99-102. PubMed ID: 20573397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?
    Chen Y
    Leuk Res; 2011 Jan; 35(1):27-9. PubMed ID: 20723974
    [No Abstract]   [Full Text] [Related]  

  • 8. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression.
    Papageorgiou SG; Pappa V; Economopoulou C; Tsirigotis P; Konsioti F; Ionnidou ED; Chondropoulos S; Vasilatou D; Papageorgiou E; Economopoulos T; Dervenoulas J
    Leuk Res; 2010 Sep; 34(9):e254-6. PubMed ID: 20392492
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenetics and pharmacogenomics as new tools to optimise cancer chemotherapy.
    Robert J
    J Chemother; 2004 Nov; 16 Suppl 4():22-4. PubMed ID: 15688604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib in chronic myelogenous leukemia.
    Chu SC; Tang JL; Li CC
    N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A once-daily dasatinib dosing strategy for chronic myeloid leukemia.
    Bryant G
    Clin J Oncol Nurs; 2009 Jun; 13(3):316-23. PubMed ID: 19502190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversing resistance to targeted therapy.
    Vidal L; Attard G; Kaye S; De Bono J
    J Chemother; 2004 Nov; 16 Suppl 4():7-12. PubMed ID: 15688600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
    Martin SE; Sausen M; Joseph A; Kingham BF
    Cancer Genet Cytogenet; 2010 Sep; 201(2):133-4. PubMed ID: 20682399
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
    Sonmez M; Cobanoglu U; Ovali E; Omay SB
    J Clin Pharm Ther; 2008 Jun; 33(3):329-30. PubMed ID: 18452422
    [No Abstract]   [Full Text] [Related]  

  • 17. [Genetic alterations and chemoresistance].
    Akiyama S
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1895-901. PubMed ID: 16282723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
    Schenone S; Brullo C; Musumeci F; Botta M
    Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
    Faber E; Mojzikova R; Plachy R; Rozmanova S; Stastny M; Divoka M; Jarosova M; Indrak K; Divoky V
    Leuk Res; 2010 Apr; 34(4):e91-3. PubMed ID: 19811824
    [No Abstract]   [Full Text] [Related]  

  • 20. Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
    Herrmann MD; Lennerz JK; Bullinger L; Bartholomae S; Holzmann K; Westhoff MA; Corbacioglu S; Debatin KM
    Exp Hematol; 2014 Feb; 42(2):90-100. PubMed ID: 24211243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.